Szyman Catherine M. has filed 28 insider transactions across 3 companies since May 2023.
Most recent transaction: a tax payment of 1069 shares of MASIMO CORP ($MASI) on March 11, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | F | Common Stock | 1069 | $175.47 | 7,605.0000 | 53,100,000 | 12.32% | 0.00% |
| March 11, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | M | Common Stock | 2101 | $0.00 | 8,674.0000 | 53,100,000 | 31.96% | 0.00% |
| March 11, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | M | Restricted Stock Units | 2101 | $0.00 | 6,306.0000 | 53,100,000 | 24.99% | 0.00% |
| March 6, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | A | Restricted Stock Units | 39904 | $0.00 | 39,904.0000 | 53,100,000 | 9999.99% | 0.08% |
| Feb. 12, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | F | Common Stock | 4568 | $0.00 | 6,573.0000 | 53,100,000 | 41.00% | 0.01% |
| Feb. 12, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | M | Common Stock | 11141 | $132.96 | 11,141.0000 | 53,100,000 | 9999.99% | 0.02% |
| Feb. 12, 2026 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | M | Restricted Stock Units | 11141 | $0.00 | 22,283.0000 | 53,100,000 | 33.33% | 0.02% |
| March 11, 2025 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | A | Restricted Stock Units | 8407 | $0.00 | 8,407.0000 | 53,600,000 | 9999.99% | 0.02% |
| March 11, 2025 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | A | Non-Qualified Stock Option (Right to Buy) | 18617 | $0.00 | 18,617.0000 | 53,600,000 | 9999.99% | 0.03% |
| Feb. 12, 2025 | MASIMO CORP | $MASI | Szyman Catherine M. | CEO | A | Restricted Stock Units | 33424 | $0.00 | 33,424.0000 | 53,600,000 | 9999.99% | 0.06% |
| Sept. 3, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | A | Common Stock | 10910 | $0.00 | 86,817.4373 | 653,500,000 | 14.37% | 0.00% |
| Sept. 3, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 5530 | $69.96 | 81,287.4373 | 653,500,000 | 6.37% | 0.00% |
| July 7, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 258 | $92.32 | 75,907.4373 | 653,500,000 | 0.34% | 0.00% |
| May 11, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 827 | $86.72 | 76,165.4373 | 651,800,000 | 1.07% | 0.00% |
| May 7, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 609 | $85.09 | 76,992.4373 | 651,800,000 | 0.78% | 0.00% |
| May 7, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | A | Common Stock | 32025 | $0.00 | 77,601.4373 | 651,800,000 | 70.27% | 0.00% |
| May 4, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 3442 | $85.25 | 45,576.4373 | 651,800,000 | 7.02% | 0.00% |
| May 4, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Performance Rights | 5796 | $0.00 | 0.0000 | 651,800,000 | 100.00% | 0.00% |
| May 4, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Common Stock | 5796 | $0.00 | 49,018.4373 | 651,800,000 | 13.41% | 0.00% |
| May 3, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | F | Common Stock | 479 | $85.06 | 43,222.4373 | 651,800,000 | 1.10% | 0.00% |
| Feb. 22, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | A | Common Stock | 8560 | $0.00 | 43,373.5710 | 650,500,000 | 24.59% | 0.00% |
| Feb. 15, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | S | Common Stock | 27000 | $85.62 | 34,813.5710 | 650,500,000 | 43.68% | 0.00% |
| Feb. 15, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Common Stock | 27000 | $36.75 | 61,813.5710 | 650,500,000 | 77.56% | 0.00% |
| Feb. 15, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Employee Stock Option (Right to Acquire) | 27000 | $0.00 | 0.0000 | 650,500,000 | 100.00% | 0.00% |
| Feb. 13, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Common Stock | 20000 | $36.75 | 54,813.5710 | 650,500,000 | 57.45% | 0.00% |
| Feb. 13, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | M | Employee Stock Option (Right to Acquire) | 20000 | $0.00 | 27,000.0000 | 650,500,000 | 42.55% | 0.00% |
| Feb. 13, 2024 | Edwards Lifesciences Corp | $EW | Szyman Catherine M. | CVP, Critical Care | S | Common Stock | 20000 | $86.46 | 34,813.5710 | 650,500,000 | 36.49% | 0.00% |
| May 31, 2023 | Outset Medical, Inc. | $OM | Szyman Catherine M. | Director | A | Common Stock | 7681 | $0.00 | 24,596.0000 | 0 | 45.41% | 0.00% |